Patient characteristics
| Number of patients | 14 | |
| Median age (range), y | 60.5 (37-89) | |
| Hormone receptor status | ||
| ER/PR status | ||
| Positive | 8 | |
| Negative | 6 | |
| Her-2 status | ||
| Positive | 4 | |
| Negative | 10 | |
| Metastatic sites | ||
| Brain | 1 | |
| Lung, liver, bones | 2 | |
| Lung | 2 | |
| Pelvic and chest wall | 1 | |
| Bone | 1 | |
| Liver and bone | 2 | |
| Distant nodes | 2 | |
| Pleura and bone | 1 | |
| Distant node and bone | 1 | |
| Liver | 1 | |
| Prior line of systemic chemotherapy for MBC | ||
| 0 | 2 | |
| 1 | 5 | |
| 2 | 7 | |
| Prior systemic trastuzumab for MBC | 3 | |
Abbreviation: PR, progesterone receptor.